When does Vabysmo go off patent?
In the US, biosimilars can launch from 2034. Vabysmo is sold by Roche. The 12-year US biologic exclusivity ends in January 2034. Roche does not publish Vabysmo's patent dates, which may run later. Eye diseases (wet AMD, diabetic macular edema). Sales CHF 4.10B.
Vabysmo's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
No US filing found No Vabysmo biosimilar is approved. The only program we found is preclinical, in China.
Checked October 2026. Sources: FDA Purple Book
Patent-expiry estimate. The 12-year US biologic exclusivity ends in January 2034. Roche does not publish Vabysmo's patent dates, which may run later. Eye diseases (wet AMD, diabetic macular edema). Sales CHF 4.10B.
Among past biologics facing biosimilars: Humira's US sales fell to 65% of their 2022 level in its first full year of biosimilars (2023) and 16% two years later; Stelara's US sales fell to 57% of their 2024 level in its first full year of biosimilars (2025). See how past cliffs played out →
Vabysmo is 6.7% of Roche's 2025 revenue (≈$4.9B of $74.1B). With Xolair, Perjeta, Tecentriq and Ocrevus, the drugs tracked here add up to 34% of Roche's revenue losing US exclusivity by 2034. Group sales CHF 61.5B, including Diagnostics.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Vabysmo is highlighted.